Company intelligence / Profile preview
Gensciences
Nantong, Jiangsu Province, Chinaen.gensciences.com ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
The company has four innovative drugs under clinical development and registration review. FRSW107 is under registration review, FRSW117 is in Phase III clinical trials, SS109 has completed Phase II clinical trials, and SS327 has been approved for clinical trials in China.
- Therapeutic areas
- HematologyOncologyMetabolic Disorders
- Modalities
- Fusion proteinsRecombinant coagulation factorsPEGylated proteins
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Foresee Pharma (Taiwan)
Beyond the preview
Go deeper on Gensciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gensciences.